%611147
Table of Contents
Cytogenetic location: 2q31 Genomic coordinates (GRCh38) : 2:168,900,001-182,100,000
For a general phenotypic description of paroxysmal nonkinesigenic dyskinesia, see PNKD1 (118800).
Spacey et al. (2006) reported a Canadian family of European descent in which 10 members spanning 4 generations had paroxysmal nonkinesigenic dyskinesia (PNKD) inherited in an autosomal dominant pattern. Affected family members presented with episodic dystonia primarily affecting the hands and feet symmetrically. Age at onset ranged from childhood to age 50 years. Episodes lasted 2 to 5 minutes (up to 10 minutes in 1 patient) and occurred daily or several times per month. Alcohol, caffeine, and excitement were not obvious triggers. Three patients also had migraines, 1 had a grand mal seizure at age 11 years, and 1 had a single infantile seizure.
By genomewide linkage analysis of a large family with PNKD, Spacey et al. (2006) identified a candidate locus, termed PNKD2, on chromosome 2q31 (parametric lod score of 2.03 and multipoint nonparametric lod score of 7.0). Haplotype analysis delineated a 10-cM interval between markers D2S2188 and D2S364, and demonstrated a disease penetrance of 89%. Linkage analysis excluded the PNKD1 locus, and molecular analysis did not identify any mutations in the MR1 (609023) or GAD1 (605363) genes.
Spacey, S. D., Adams, P. J., Lam, P. C. P., Materek, L. A., Stoessl, A. J., Snutch, T. P., Hsiung, G.-Y. R. Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. Neurology 66: 1588-1590, 2006. [PubMed: 16717228, related citations] [Full Text]
Alternative titles; symbols
ORPHA: 98810; DO: 0090047;
Cytogenetic location: 2q31 Genomic coordinates (GRCh38) : 2:168,900,001-182,100,000
| Location | Phenotype |
Phenotype MIM number |
Inheritance |
Phenotype mapping key |
|---|---|---|---|---|
| 2q31 | Paroxysmal nonkinesigenic dyskinesia 2 | 611147 | Autosomal dominant | 2 |
For a general phenotypic description of paroxysmal nonkinesigenic dyskinesia, see PNKD1 (118800).
Spacey et al. (2006) reported a Canadian family of European descent in which 10 members spanning 4 generations had paroxysmal nonkinesigenic dyskinesia (PNKD) inherited in an autosomal dominant pattern. Affected family members presented with episodic dystonia primarily affecting the hands and feet symmetrically. Age at onset ranged from childhood to age 50 years. Episodes lasted 2 to 5 minutes (up to 10 minutes in 1 patient) and occurred daily or several times per month. Alcohol, caffeine, and excitement were not obvious triggers. Three patients also had migraines, 1 had a grand mal seizure at age 11 years, and 1 had a single infantile seizure.
By genomewide linkage analysis of a large family with PNKD, Spacey et al. (2006) identified a candidate locus, termed PNKD2, on chromosome 2q31 (parametric lod score of 2.03 and multipoint nonparametric lod score of 7.0). Haplotype analysis delineated a 10-cM interval between markers D2S2188 and D2S364, and demonstrated a disease penetrance of 89%. Linkage analysis excluded the PNKD1 locus, and molecular analysis did not identify any mutations in the MR1 (609023) or GAD1 (605363) genes.
Spacey, S. D., Adams, P. J., Lam, P. C. P., Materek, L. A., Stoessl, A. J., Snutch, T. P., Hsiung, G.-Y. R. Genetic heterogeneity in paroxysmal nonkinesigenic dyskinesia. Neurology 66: 1588-1590, 2006. [PubMed: 16717228] [Full Text: https://doi.org/10.1212/01.wnl.0000217332.51740.7c]
Dear OMIM User,
To ensure long-term funding for the OMIM project, we have diversified our revenue stream. We are determined to keep this website freely accessible. Unfortunately, it is not free to produce. Expert curators review the literature and organize it to facilitate your work. Over 90% of the OMIM's operating expenses go to salary support for MD and PhD science writers and biocurators. Please join your colleagues by making a donation now and again in the future. Donations are an important component of our efforts to ensure long-term funding to provide you the information that you need at your fingertips.
Thank you in advance for your generous support,
Ada Hamosh, MD, MPH
Scientific Director, OMIM